Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Shares of Ginkgo Bioworks Holdings, Inc. (DNA) have gained 2% over the past four weeks to close the last trading session at $6.78, but there could still be a solid upside left in the stock if ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Reshma Shetty co-founded Ginkgo Bioworks in 2008, a leading organism design company. As President and COO, she has overseen ...

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...